Global Difficult-to-Express Proteins Market Size study, By Protein (Proteases, Kinases, Membrane Proteins, Others), By Technology (Cell-free Protein Synthesis, Prokaryotic Expression Systems, SUMO Fusion System, Gene Fusion Systems, Others), By Applicatio

Global Difficult-to-Express Proteins Market Size study, By Protein (Proteases, Kinases, Membrane Proteins, Others), By Technology (Cell-free Protein Synthesis, Prokaryotic Expression Systems, SUMO Fusion System, Gene Fusion Systems, Others), By Application (Drug Discovery, Protein Purification, Protein Therapeutics, Disease Diagnostics and Monitoring, Others), and Regional Forecasts 2022-2028

Global Difficult-to-Express Proteins Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Difficult-to-Express Proteins can be defined as proteins that cannot be easily synthesized in conventional in vivo protein production platforms. These proteins do not emerge in fully soluble, well-folded, and active form in a heterologous expression system due to their inherent properties. Proteins such as proteases, kinases, membrane proteins are considered as difficult to express proteins. The growing prevalence of chronic diseases and increasing end use applications of difficult-to-express proteins as well as recent clinical trials towards high proteins are accelerating the global market demand. For instance, according to World Health Organization (WHO) estimate – as of 2019, globally around 17.9 million people succumbs to cardiovascular diseases (CVDs), witnessing for 32% of all global deaths. Further, 85% of death were caused by heart attack and stroke. Moreover, in October 2021, Germany based Eleva, a leading manufacturer of superior biologics announced clinical development of Difficult-To-Express high-potential proteins. The company would produce complex proteins for future therapies, such as 2nd generation oncological therapeutics, and virus-like-particles (VLP) for vaccine development. Also, growing investment towards healthcare research and rising healthcare sector in emerging economics are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, a high cost associated with these proteins impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Difficult-to-Express Proteins Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing spending on healthcare research activities and presence of leading pharma players in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as the thriving growth of clinical research organizations and increasing penetration of leading market players in the region, would create lucrative growth prospects for the global Difficult-to-Express Proteins Market across the Asia Pacific region.

Major market players included in this report are:
R&D Systems
Enzo Life Sciences
Sino Biological
Thermo Fisher Scientific
StressMarq Biosciences
LifeSensors Inc.
Lucigen
Batavia Biosciences Inc.
WuXi Biologics
Selexis SA

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Protein
Proteases
Kinases
Membrane Proteins
Others
By Technology
Cell-free Protein Synthesis
Prokaryotic Expression Systems
SUMO Fusion System
Gene Fusion Systems
Others
By Application
Drug Discovery
Protein Purification
Protein Therapeutics
Disease Diagnostics and Monitoring
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Difficult-to-Express Proteins Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors



Companies Mentioned

R&D Systems
Enzo Life Sciences
Sino Biological
Thermo Fisher Scientific
StressMarq Biosciences
LifeSensors Inc.
Lucigen
Batavia Biosciences Inc.
WuXi Biologics
Selexis SA

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.